Welgus Howard G. sold $116K of ARQT

Welgus Howard G. sold 4,731 shares of Arcutis Biotherapeutics, Inc. (ARQT) at an average of $24.58 ($24.41–$25.67, $0.12M total) across 2 trades over 2026-06-15 to 2026-06-17 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Welgus Howard G.
Published Jun 18, 2026, 12:40 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 18, 2026, 1:05 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ARQT
Neutral
high confidence
Mentioned
$ARQT
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ARQTNeutralLow
01

Why it matters

The disclosure provides a new, dated record of insider selling but does not include any new company performance, regulatory, or product-development information.

02

Market read

Traders may briefly reassess sentiment around ARQT due to insider selling, but the pre-arranged nature and lack of fundamentals limit trading edge.

03

What to watch

The sale size (~$116K) is small relative to typical biotech market caps; without additional context (e.g., other insiders selling/buying), signal strength is weak.

Relevance 3/10Novelty 2/10Timing: Filed 2026-06-17 for trades dated 2026-06-15 to 2026-06-17

Background

SEC Form 4 reports an insider transaction by a director of Arcutis Biotherapeutics, Inc. (ARQT).

Company-level read

Ticker impact

$ARQTNeutralHigh confidence
Context

Arcutis Biotherapeutics director Welgus Howard G sold 4,731 ARQT shares in open-market trades under a 10b5-1 plan for ~$116.3K.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven and small.

Evidence & confidence

The filing is a Form 4 detailing a pre-arranged 10b5-1 sale with no accompanying company-specific operational or financial change.

Market effects

No clear sector read-through; this is an issuer-specific insider transaction.

None indicated.

None indicated.

Counterpoint

Even 10b5-1 sales can coincide with private information, so traders may watch for follow-on insider activity or subsequent guidance/clinical updates.

Key entities

  • Arcutis Biotherapeutics, Inc.

    Issuer of ARQT shares; subject of the Form 4 insider sale disclosure.

  • Welgus Howard G.

    Director who sold 4,731 ARQT shares in open-market trades under a pre-arranged 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ARQTHighAI 8/10

Arcutis reports trial data on infant eczema treatment candidate

Arcutis Biotherapeutics (ARQT) presented INTEGUMENT-INFANT trial data for ZORYVE cream 0.05% in treating infant atopic dermatitis. The study showed no serious adverse events, with 66.7% of infants reporting itch improvement within 4 hours. The cream is approved for children 2-5 years and is under FDA review for infants 3-24 months, with a decision expected by February 23, 2027.

$ARQTMed

Arcutis (ARQT) Q3 2026 Earnings Call Transcript

Arcutis Biotherapeutics (ARQT) reported Q3 2026 revenue of $143.9M, up 45% YoY, driven by ZORYVE franchise growth. Full-year revenue guidance raised to $535M-$545M. Net income was $8.8M, with cash and securities at $259.8M. The company plans to invest in commercial initiatives for 2027 growth, focusing on dermatology and primary care.

$ARQTMedAI 8/10

TD Cowen raises Arcutis stock price target on Zoryve momentum

TD Cowen raised its price target for Arcutis Biotherapeutics (ARQT) to $40 from $35, citing strong Zoryve sales of $144M and raised 2026 guidance. Revenue grew 11% quarter-over-quarter and 45% year-over-year, with a 91% gross profit margin. The stock trades near its 52-week high at $34.05. Arcutis reported Q3 2026 revenue of $143.9M, beating estimates, but missed profit expectations.